The anti-inflammatory and immunological properties of SGLT-2 inhibitors

被引：29

作者：

Bendotti, G. ^{[1
,2
]}

Montefusco, L. ^{[1
]}

Pastore, I. ^{[1
]}

Lazzaroni, E. ^{[1
]}

Lunati, M. E. ^{[1
]}

Fiorina, P. ^{[1
,3
,4
]}

机构：

[1] ASST Fatebenefratelli Sacco, Div Endocrinol, Milan, Italy

[2] AO SS Antonio & Biagio & Cesare Arrigo, Endocrinol & Metab Dis Unit, Alessandria, Italy

[3] Univ Milan, Int Ctr T1D, Pediat Clin Res Ctr Romeo Enrica Invernizzi, Dept Biomed & Clin Sci L Sacco, Milan, Italy

[4] Harvard Med Sch, Boston Childrens Hosp, Nephrol Div, 300 Longwood Ave,Enders Bldg 5th Floor En511, Boston, MA 02115 USA

来源：

JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION | 2023年 / 46卷 / 12期

关键词：

SGLT-2; inhibitors; Inflammation; Immune system; Immune cells; Cytokines; KIDNEY-PANCREAS TRANSPLANTATION; OXIDATIVE STRESS; INFLAMMATION; CANAGLIFLOZIN; MECHANISM;

D O I：

10.1007/s40618-023-02162-9

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BackgroundSodium-glucose cotransporter-2 inhibitors (SGLT-2i) are antidiabetic oral drugs that act on proximal renal tubules promoting renal glucose excretion. Although SGLT-2i belong to the class of hypoglycemic agents, in the last years great interest has emerged in studying their pleiotropic effects, beyond their ability to lower glucose levels.PurposeIn this review we are describing the anti-inflammatory and immunological properties of SGLT-2i; furthermore, we are addressing how the mechanisms associated with the aforementioned anti-inflammatory properties may contribute to the beneficial effects of SGLT-2i in diabetes.MethodsA systematic search was undertaken for studies related the properties of SGLT-2i in reducing the inflammatory milieu of acute and chronic disease by acting on the immune system, independently by glycemia.ResultsRecently, some data described the anti-inflammatory and immunological properties of SGLT-2 in both pre-clinical and clinical studies. Numerous data confirmed the cardio- and -renal protective effects of SGLT-2i in patients with heart failure and kidney diseases, with or without diabetes.ConclusionsSGLT-2i are promising drugs with anti-inflammatory and immunological properties. Despite the mechanism of action of SGLT-2i is not fully understood, these drugs demonstrated anti-inflammatory effects, which may help in keeping under control the variety of complications associated with diabetes.

引用

页码：2445 / 2452

页数：8

共 82 条

[61] Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy [J].

Perkovic, V. ;

Jardine, M. J. ;

Neal, B. ;

Bompoint, S. ;

Heerspink, H. J. L. ;

Charytan, D. M. ;

Edwards, R. ;

Agarwal, R. ;

Bakris, G. ;

Bull, S. ;

Cannon, C. P. ;

Capuano, G. ;

Chu, P. -L. ;

De Zeeuw, D. ;

Greene, T. ;

Levin, A. ;

Pollock, C. ;

Wheeler, D. C. ;

Yavin, Y. ;

Zhang, H. ;

Zinman, B. ;

Meininger, G. ;

Brenner, B. M. ;

Mahaffey, K. W. ;

McGuire, Darren K. ;

Holman, Rury ;

Home, Philip ;

Scharfstein, Dan ;

Parfrey, Patrick ;

Shahinfar, Shahnaz ;

August, Phyllis ;

Chang, Tara ;

Sinha, Arjun D. ;

Januzzi, James ;

Kolansky, Daniel ;

Amerena, John ;

Hillis, Graham ;

Gorelick, Philip ;

Kissela, Brett ;

Kasner, Scott ;

Lindley, Richard ;

Fulcher, Greg ;

Ounadjela, Souhila ;

Hufert, Karina ;

von Ingersleben, Gabriele ;

Gaglia, Jason ;

Harris, Ronald ;

Hudson, Margo ;

Turchin, Alexander ;

Cheifetz, Adam .

NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (24) :2295-2306

[62] Cross-sectional assessment of the effect of kidney and kidney-pancreas transplantation on resting left ventricular energy metabolism in type 1 diabetic-uremic patients - A phosphorous-31 magnetic resonance spectroscopy study [J].

Perseghin, G ;

Fiorina, P ;

De Cobelli, F ;

Scifo, P ;

Esposito, A ;

Canu, T ;

Danna, M ;

Gremizzi, C ;

Secchi, A ;

Luzi, L ;

Del Maschio, A .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 46 (06) :1085-1092

[63] The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin [J].

Quagliariello, Vincenzo ;

De Laurentiis, Michelino ;

Rea, Domenica ;

Barbieri, Antonio ;

Monti, Maria Gaia ;

Carbone, Andreina ;

Paccone, Andrea ;

Altucci, Lucia ;

Conte, Mariarosaria ;

Canale, Maria Laura ;

Botti, Gerardo ;

Maurea, Nicola .

CARDIOVASCULAR DIABETOLOGY, 2021, 20 (01)

[64] Cardioprotective effects of short-term empagliflozin treatment in db/db mice [J].

Radlinger, Bernhard ;

Hornsteiner, Florian ;

Folie, Sabrina ;

Salvenmoser, Willi ;

Haubner, Bernhard J. ;

Schuetz, Thomas ;

Haas, Simone ;

Ress, Claudia ;

Adolph, Timon E. ;

Salzmann, Karin ;

Weiss, Bernhard ;

Tilg, Herbert ;

Kaser, Susanne .

SCIENTIFIC REPORTS, 2020, 10 (01)

[65] Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease [J].

Ridker, P. M. ;

Everett, B. M. ;

Thuren, T. ;

MacFadyen, J. G. ;

Chang, W. H. ;

Ballantyne, C. ;

Fonseca, F. ;

Nicolau, J. ;

Koenig, W. ;

Anker, S. D. ;

Kastelein, J. J. P. ;

Cornel, J. H. ;

Pais, P. ;

Pella, D. ;

Genest, J. ;

Cifkova, R. ;

Lorenzatti, A. ;

Forster, T. ;

Kobalava, Z. ;

Vida-Simiti, L. ;

Flather, M. ;

Shimokawa, H. ;

Ogawa, H. ;

Dellborg, M. ;

Rossi, P. R. F. ;

Troquay, R. P. T. ;

Libby, P. ;

Glynn, R. J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (12) :1119-1131

[66] Effects of Sodium-Glucose Transporter 2 Inhibitors (SGLT2-I) in Patients With Ischemic Heart Disease (IHD) Treated by Coronary Artery Bypass Grafting via MiECC: Inflammatory Burden, and Clinical Outcomes at 5 Years of Follow-Up [J].

Sardu, Celestino ;

Massetti, Massimo ;

Testa, Nicola ;

Martino, Luigi Di ;

Castellano, Gaetano ;

Turriziani, Fabrizio ;

Sasso, Ferdinando Carlo ;

Torella, Michele ;

De Feo, Marisa ;

Santulli, Gaetano ;

Paolisso, Giuseppe ;

Marfella, Raffaele .

FRONTIERS IN PHARMACOLOGY, 2021, 12

[67]

Schlosser J., 2022, DIABETES CARE, V45, pS125, DOI [10.2337/dc22-S009, DOI 10.2337/DC22-S009]

[68] A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors [J].

Sen, Taha ;

Heerspink, Hiddo J. L. .

CELL METABOLISM, 2021, 33 (04) :732-739

[69] The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion [J].

Sukhanov, Sergiy ;

Higashi, Yusuke ;

Yoshida, Tadashi ;

Mummidi, Srinivas ;

Aroor, Annayya R. ;

Russell, Jacob Jeffrey ;

Bender, Shawn B. ;

DeMarco, Vincent G. ;

Chandrasekar, Bysani .

CELLULAR SIGNALLING, 2021, 77

[70] SGLT2 Inhibition Mediates Protection from Diabetic Kidney Disease by Promoting Ketone Body-Induced mTORC1 Inhibition [J].

Tomita, Issei ;

Kume, Shinji ;

Sugahara, Sho ;

Osawa, Norihisa ;

Yamahara, Kosuke ;

Yasuda-Yamahara, Mako ;

Takeda, Naoko ;

Chin-Kanasaki, Masami ;

Kaneko, Tatsuroh ;

Mayoux, Eric ;

Mark, Michael ;

Yanagita, Motoko ;

Ogita, Hisakazu ;

Araki, Shin-ichi ;

Maegawa, Hiroshi .

CELL METABOLISM, 2020, 32 (03) :404-+

← 1 2 3 4 5 6 7 8 9 →